151 related articles for article (PubMed ID: 36350752)
1. The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients.
Sourisseau M; Faure E; Béhal H; Chauvet P; Srour M; Capes A; Coiteux V; Magro L; Alfandari S; Alidjinou EK; Simon N; Vuotto F; Karam M; Faure K; Yakoub-Agha I; Beauvais D
Blood Adv; 2023 Mar; 7(5):856-865. PubMed ID: 36350752
[TBL] [Abstract][Full Text] [Related]
2. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide-based transplant.
Lin A; Brown S; Chinapen S; Lee YJ; Seo SK; Ponce DM; Shahid Z; Giralt S; Papanicolaou GA; Perales MA; Shaffer BC
Blood Adv; 2023 Dec; 7(23):7153-7160. PubMed ID: 37906513
[TBL] [Abstract][Full Text] [Related]
3. Extended duration letermovir in allogeneic hematopoietic stem cell transplant.
Hinman B; Cox J; Umoru G; Kamble R; Musick W
Transpl Immunol; 2023 Dec; 81():101936. PubMed ID: 37770000
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of letermovir for cytomegalovirus prophylaxis in allogeneic hematopoietic stem cell transplant recipients: A global systematic review.
Sepassi A; Saunders IM; Bounthavong M; Taplitz RA; Logan C; Watanabe JH
J Am Pharm Assoc (2003); 2023; 63(4):1138-1149. PubMed ID: 37207713
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, Safety, and Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Adolescent Hematopoietic Cell Transplantation Recipients.
Groll AH; Schulte JH; Antmen AB; Fraser CJ; Teal VL; Haber B; Caro L; McCrea JB; Fancourt C; Patel M; Menzel K; Badshah C
Pediatr Infect Dis J; 2024 Mar; 43(3):203-208. PubMed ID: 38241643
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study.
Nho D; Lee R; Cho SY; Lee DG; Kim EJ; Park S; Lee SE; Cho BS; Kim YJ; Lee S; Kim HJ
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766290
[TBL] [Abstract][Full Text] [Related]
7. Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study.
Brusosa M; Ruiz S; Monge I; Solano MT; Rosiñol L; Esteve J; Carreras E; Marcos MÁ; Riu G; Carcelero E; Martinez C; Fernández-Avilés F; Rovira M; Suárez-Lledó M; Salas MQ
Ann Hematol; 2024 Feb; 103(2):609-621. PubMed ID: 37957371
[TBL] [Abstract][Full Text] [Related]
8. Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP).
Galaverna F; Baccelli F; Zama D; Tridello G; Masetti R; Soncini E; Mura R; Barzaghi F; Colombini A; Prunotto G; D'Amico MR; Calore E; Biffi A; Perruccio K; Gasperini P; Oltolini C; Quagliarella F; Giacomazzi A; Pagliara D; Locatelli F; Cesaro S
Bone Marrow Transplant; 2024 Apr; 59(4):505-512. PubMed ID: 38272999
[TBL] [Abstract][Full Text] [Related]
9. CMV prevention strategies in allogeneic hematopoietic cell transplantation; the role of prophylaxis and pre-emptive monitoring in the era of letermovir.
Yong MK; Slavin MA; Chemaly RF; Papanicolaou GA
Transpl Infect Dis; 2023 Nov; 25 Suppl 1():e14171. PubMed ID: 37864299
[TBL] [Abstract][Full Text] [Related]
10. Letermovir for Cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation.
Chen TT; David AP; Barthelmess EK; MacBrayne CE
Pediatr Blood Cancer; 2023 Nov; 70(11):e30608. PubMed ID: 37548491
[TBL] [Abstract][Full Text] [Related]
11. Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data.
Pang I; Chen P; Trinh GV; Remberger M; Novitzky-Basso I; Gerbitz A; Kim DD; Kumar R; Lam W; Law AD; Lipton JH; Viswabandya A; Pasic I; Mattsson J; Michelis FV
Eur J Haematol; 2024 Feb; 112(2):301-309. PubMed ID: 37830403
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus breakthrough and resistance during letermovir prophylaxis.
Perchetti GA; Biernacki MA; Xie H; Castor J; Joncas-Schronce L; Ueda Oshima M; Kim Y; Jerome KR; Sandmaier BM; Martin PJ; Boeckh M; Greninger AL; Zamora D
Bone Marrow Transplant; 2023 Apr; 58(4):430-436. PubMed ID: 36693927
[TBL] [Abstract][Full Text] [Related]
13. Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysis.
Toya T; Mizuno K; Sakurai M; Kato J; Mori T; Doki N; Masuda S; Aotsuka N; Tsukamoto S; Sakaida E; Nakajima Y; Fujisawa S; Machida S; Aoyama Y; Yokoyama H; Shono K; Hatta Y; Usuki K; Kataoka K; Kanda Y
Blood Adv; 2024 Mar; 8(5):1084-1093. PubMed ID: 38330190
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infection.
Takenaka K; Fuji S; Matsukawa T; Uchida N; Kobayashi T; Tanaka M; Ara T; Ikegame K; Ozawa Y; Kanda Y; Sawa M; Maruyama Y; Fukuda T; Nakamae H; Kimura T; Ogata M; Seo S; Atsuta Y; Matsuo K; Nakasone H
Ann Hematol; 2024 Jan; 103(1):285-296. PubMed ID: 37947825
[TBL] [Abstract][Full Text] [Related]
15. Letermovir for cytomegalovirus infection in allogeneic hematopoietic stem-cell transplantation: tips and notes for effective use in clinical practice.
Ohmoto A; Fuji S
Expert Rev Anti Infect Ther; 2024 Apr; 22(4):169-178. PubMed ID: 38404258
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective.
Alsumali A; Chemaly RF; Graham J; Jiang Y; Merchant S; Miles L; Schelfhout J; Yang J; Tang Y
J Med Virol; 2021 Jun; 93(6):3786-3794. PubMed ID: 32844453
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, Safety, and Cost-effectiveness Analysis of Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Qiu Y; Zhang Y; Teng M; Cheng S; Du Q; Yang L; Wang Q; Wang T; Wang Y; Dong Y; Dong H
Transplantation; 2024 Apr; 108(4):1021-1032. PubMed ID: 38049935
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic analysis driven letermovir dosing in pediatric hematopoietic cell transplantation patients with resistant CMV disease.
Pai VB; Tansmore J; Song E
Pediatr Transplant; 2024 Feb; 28(1):e14580. PubMed ID: 37466088
[TBL] [Abstract][Full Text] [Related]
19. Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan.
Fukuda M; Hattori J; Ohkubo R; Watanabe A; Maekawa S
Clin Drug Investig; 2024 Jun; ():. PubMed ID: 38935253
[TBL] [Abstract][Full Text] [Related]
20. Letermovir Effectively Prevents Cytomegalovirus Infection in Patients with Aplastic Anemia After Hematopoietic Stem Cell Transplantation: A Real-World Retrospective Cohort Study.
Zhang Y; Chen X; Zhou M; Zhang Y; Chen C; Zhou R; Li Y; Yang F; Xu S; Wang C; Zhou W; Deng T; Pan S; Mo W; Wang S
Infect Dis Ther; 2024 Feb; 13(2):345-359. PubMed ID: 38265628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
